Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer R de Wit, J de Bono, CN Sternberg, K Fizazi, B Tombal, C Wülfing, ... New England Journal of Medicine 381 (26), 2506-2518, 2019 | 568 | 2019 |
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial A Sverrisdottir, M Nystedt, H Johansson, T Fornander Breast cancer research and treatment 117, 561-567, 2009 | 183 | 2009 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history E Kimby, A Sverrisdottir, G Elinder European journal of haematology 72 (4), 292-295, 2004 | 170 | 2004 |
Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy A Sverrisdottir, T Fornander, H Jacobsson, E Von Schoultz, LE Rutqvist Journal of clinical oncology 22 (18), 3694-3699, 2004 | 161 | 2004 |
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative P Aftimos, M Oliveira, A Irrthum, D Fumagalli, C Sotiriou, EN Gal-Yam, ... Cancer discovery 11 (11), 2796-2811, 2021 | 92 | 2021 |
Changes in attitudes, practices and barriers among oncology health care professionals regarding sexual health care: Outcomes from a 2-year educational intervention at a … JI Jonsdottir, S Zoëga, T Saevarsdottir, A Sverrisdottir, T Thorsdottir, ... European Journal of Oncology Nursing 21, 24-30, 2016 | 86 | 2016 |
A common variant at 8q24. 21 is associated with renal cell cancer J Gudmundsson, P Sulem, DF Gudbjartsson, G Masson, V Petursdottir, ... Nature communications 4 (1), 2776, 2013 | 70 | 2013 |
Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian Prostate … GM Ahlgren, P Flodgren, TLJ Tammela, P Kellokumpu-Lehtinen, M Borre, ... European urology 73 (6), 870-876, 2018 | 64 | 2018 |
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised … K Fizazi, G Kramer, JC Eymard, CN Sternberg, J De Bono, D Castellano, ... The Lancet Oncology 21 (11), 1513-1525, 2020 | 58 | 2020 |
Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer A Sverrisdottir, H Johansson, U Johansson, J Bergh, S Rotstein, ... Breast cancer research and treatment 128, 755-763, 2011 | 42 | 2011 |
Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers M Aradottir, ST Reynisdottir, OA Stefansson, JG Jonasson, A Sverrisdottir, ... The Journal of Pathology: Clinical Research 1 (1), 33-40, 2015 | 27 | 2015 |
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin®) on a named patient basis in Sweden J Andersson, B Linderholm, G Greim, B Lindh, H Lindman, J Tennvall, ... Acta Oncologica 41 (3), 276-281, 2002 | 23 | 2002 |
Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study CN Sternberg, D Castellano, J de Bono, K Fizazi, B Tombal, C Wülfing, ... European urology 80 (4), 497-506, 2021 | 22 | 2021 |
A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: results of SPCG12. G Ahlgren, P Flodgren, TLJ Tammela, P Kellokumpu-Lehtinen, M Borre, ... Journal of Clinical Oncology 34 (15_suppl), 5001-5001, 2016 | 19 | 2016 |
CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) R de Wit, G Kramer, JC Eymard, JS de Bono, CN Sternberg, K Fizazi, ... Annals of Oncology 30, v882-v883, 2019 | 18 | 2019 |
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel … R de Wit, C Wülfing, D Castellano, G Kramer, JC Eymard, CN Sternberg, ... ESMO open 6 (5), 100241, 2021 | 14 | 2021 |
BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy OA Stefansson, H Hilmarsdottir, K Olafsdottir, L Tryggvadottir, ... JNCI Cancer Spectrum 4 (2), pkz100, 2020 | 14 | 2020 |
Radiation-induced cell cycle response in lymphocytes is not related to clinical side-effects in breast cancer patients. R Tell, MR Edgren, A Sverrisdottir, J Castro, T Fornander, LO Hansson, ... Anticancer research 23 (3C), 3077-3083, 2003 | 13 | 2003 |
A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma X Liu, JJ Swen, MHM Diekstra, E Boven, D Castellano, H Gelderblom, ... Clinical Cancer Research 24 (10), 2350-2356, 2018 | 11 | 2018 |
Hepatotoxicity associated with ribociclib among breast cancer patients S Finnsdottir, A Sverrisdottir, ES Björnsson Acta Oncologica 60 (2), 195-198, 2021 | 9 | 2021 |